Considerations for drug trials in hypertrophic cardiomyopathy
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant+17 more
wiley +1 more source
Reframing the role of glucagon‐like peptide 1 receptor agonists in cardiovascular medicine
ESC Heart Failure, Volume 12, Issue 2, Page 923-926, April 2025.
Riccardo M. Inciardi+3 more
wiley +1 more source
Functional Anatomy of the Sheep Heart as a Model for Testing Cardiovascular Devices. [PDF]
Rusakova YL, Zhuravleva IY.
europepmc +1 more source
CMR Left Ventricular Filling Pressure Exhibits Strong Haemodynamic Relevance and Outperforms Echocardiography in Multimodal Heart Failure Assessment. [PDF]
Bana A+17 more
europepmc +1 more source
Comparison between semi-automatic and manual left atrial strain analysis in patients undergoing CABG: feasibility, reproducibility, and clinical implications. [PDF]
Wang YH+6 more
europepmc +1 more source
The Impact of Semaglutide on Cardiac Mass and Function Requires Further Investigation. [PDF]
Xu Q, Mao Y, Weng X, Shen L, Ge J.
europepmc +1 more source
Pathophysiological mechanisms of Postural Orthostatic Tachycardia Syndrome analyzed by means of hemodynamics. [PDF]
Wei L+9 more
europepmc +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1514-1522, April 2025.
Takamasa Iwai+4 more
wiley +1 more source